207 related articles for article (PubMed ID: 33807051)
1. A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab.
Backhus J; Neumann C; Perkhofer L; Schulte LA; Mayer B; Seufferlein T; Müller M; Kleger A
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807051
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
Ebbo M; Grados A; Samson M; Groh M; Loundou A; Rigolet A; Terrier B; Guillaud C; Carra-Dallière C; Renou F; Pozdzik A; Labauge P; Palat S; Berthelot JM; Pennaforte JL; Wynckel A; Lebas C; Le Gouellec N; Quémeneur T; Dahan K; Carbonnel F; Leroux G; Perlat A; Mathian A; Cacoub P; Hachulla E; Costedoat-Chalumeau N; Harlé JR; Schleinitz N
PLoS One; 2017; 12(9):e0183844. PubMed ID: 28915275
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease.
Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L
Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
6. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature.
Nikolic S; Panic N; Hintikka ES; Dani L; Rutkowski W; Hedström A; Steiner C; Löhr JM; Vujasinovic M
Scand J Gastroenterol; 2021 Nov; 56(11):1355-1362. PubMed ID: 34410885
[TBL] [Abstract][Full Text] [Related]
8. IgG4-related uveitis. A French cohort and literature review.
Stuchfield-Denby E; De Sainte Marie B; Hie M; Hatchuel Y; Gerber A; Bencheikh S; Pugnet G; Groh M; Farhat MM; Urbina D; Ebbo M; Schleinitz N
Semin Arthritis Rheum; 2024 Feb; 64():152278. PubMed ID: 38000318
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis.
Liu Y; Jin K; Yang Y; Yang A
Eur J Intern Med; 2024 Jun; ():. PubMed ID: 38871563
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.
Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH
Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556
[TBL] [Abstract][Full Text] [Related]
11. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain.
Quero M; Draibe J; Solanich X; Rama I; Gomà M; Martínez-Valenzuela L; Fulladosa X; Cruzado JM; Torras J
Clin Kidney J; 2019 Dec; 12(6):829-835. PubMed ID: 31807295
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.
Hart PA; Topazian MD; Witzig TE; Clain JE; Gleeson FC; Klebig RR; Levy MJ; Pearson RK; Petersen BT; Smyrk TC; Sugumar A; Takahashi N; Vege SS; Chari ST
Gut; 2013 Nov; 62(11):1607-15. PubMed ID: 22936672
[TBL] [Abstract][Full Text] [Related]
14. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin G4-Related Disease Responder Index Correlates With the Risk of 1-Year Relapse in Type 1 Autoimmune Pancreatitis.
Rogger TM; De Marchi G; Brozzi L; Amodio A; Orsolini G; de Pretis N; Conti Bellocchi MC; Crinò SF; Gabbrielli A; Ciccocioppo R; Frulloni L
Pancreas; 2021 Jul; 50(6):879-881. PubMed ID: 34347736
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis.
Lanzillotta M; Della-Torre E; Wallace ZS; Stone JH; Karadag O; Fernández-Codina A; Arcidiacono PG; Falconi M; Dagna L; Capurso G
Pancreatology; 2021 Oct; 21(7):1395-1401. PubMed ID: 34244040
[TBL] [Abstract][Full Text] [Related]
17. Republished: recent advances in autoimmune pancreatitis: type 1 and type 2.
Kamisawa T; Chari ST; Lerch MM; Kim MH; Gress TM; Shimosegawa T
Postgrad Med J; 2014 Jan; 90(1059):18-25. PubMed ID: 24336310
[TBL] [Abstract][Full Text] [Related]
18. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment.
Lee HW; Moon SH; Kim MH; Cho DH; Jun JH; Nam K; Song TJ; Park DH; Lee SS; Seo DW; Lee SK
J Gastroenterol; 2018 Aug; 53(8):967-977. PubMed ID: 29362937
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as Maintenance Therapy in Type 1 Autoimmune Pancreatitis: An Italian Experience.
De Marchi G; de Pretis N; Gabrieletto EM; Amodio A; Davì V; Crinò SF; Gabbrielli A; Ciccocioppo R; Frulloni L
Pancreas; 2021 Nov-Dec 01; 50(10):1363-1367. PubMed ID: 35041334
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
